Corvus Pharmaceuticals, Inc. (CRVS)
15.19
+0.50
(+3.40%)
USD |
NASDAQ |
Apr 06, 11:32
Corvus Pharmaceuticals Enterprise Value : 1.178B for April 2, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Regeneron Pharmaceuticals, Inc. | 74.90B |
| Plus Therapeutics, Inc. | 12.14M |
| Geron Corp. | 955.08M |
| Nektar Therapeutics | 1.235B |
| Jaguar Health, Inc. | 30.10M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.32M |
| Total Expenses (Quarterly) | 12.32M |
| EPS Diluted (Quarterly) | -0.1485 |
| Earnings Yield | -3.33% |
| Normalized Earnings Yield | -4.992 |